Peroxisome Proliferator-Activated Receptor-Gamma Activation in Peritoneal Dialysis Patients

Phase 4 Completed 160 enrolled The University of Hong Kong Baxter Healthcare Corporation · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To study whether peroxisome proliferator-activated receptor-gamma activation in peritoneal dialysis patients will reduce inflammation, atherosclerosis, calcification and improve survival of peritoneal dialysis patients

Timeline

Start: 2006-02
Primary completion: 2014-10
Completion: 2014-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pioglitazone	Small molecule	30 mg	—

Peroxisome Proliferator-Activated Receptor-Gamma Activation in Peritoneal Dialysis Patients

Summary

Timeline

Drugs

Indications